Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00246324 · ClinicalTrials.gov registry record · Phase 4
Safety and Efficacy Study of Doxycycline in Combination With Interferon-B-1a to Treat Multiple Sclerosis
A Phase 4 study, sponsored by Louisiana State University Health Sciences Center Shreveport.
- Completed
- Registry status
- Phase 4
- Development phase
- 16
- Enrollment target
NCT00246324 is a Phase 4 study that has completed, run by Louisiana State University Health Sciences Center Shreveport. The registered enrollment target is 16 participants.
The verdict
NCT00246324, a Phase 4 study, has completed, sponsored by Louisiana State University Health Sciences Center Shreveport.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 16 participants
- Enrollment target
Study Summary
To evaluate the efficacy, safety, and tolerability of combination therapy with intramuscular interferon beta-1a and oral doxycycline, a potent inhibitor of matrix metalloproteinases, in patients with relapsing remitting multiple sclerosis (RRMS) having breakthrough disease activity.
Interventions
- DRUG Interferon beta 1a, oral doxycycline
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2003-12 |
| Est. Completion | 2009-10 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00246324
The ClinicalTrials.gov registry entry for NCT00246324 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Louisiana State University Health Sciences Center Shreveport, which has 40 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Interferon beta 1a, oral doxycycline is the first listed.
NCT00246324 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00246324 about?
NCT00246324 is a clinical study titled "Safety and Efficacy Study of Doxycycline in Combination With Interferon-B-1a to Treat Multiple Sclerosis". To evaluate the efficacy, safety, and tolerability of combination therapy with intramuscular interferon beta-1a and oral doxycycline, a potent inhibitor of matrix metalloproteinases, in patients with relapsing remitting multiple sclerosis (RRMS) having breakthrough disease activity.
What is the current status of trial NCT00246324?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 16 participants. The study started on 2003-12. Estimated completion is 2009-10.
What interventions are being tested in trial NCT00246324?
The interventions under investigation include: Interferon beta 1a, oral doxycycline (DRUG).
Who is sponsoring clinical trial NCT00246324?
This trial is sponsored by Louisiana State University Health Sciences Center Shreveport, which has 40 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.